156 related articles for article (PubMed ID: 1776885)
1. Compliance assessed by the Medication Event Monitoring System.
Olivieri NF; Matsui D; Hermann C; Koren G
Arch Dis Child; 1991 Dec; 66(12):1399-402. PubMed ID: 1776885
[TBL] [Abstract][Full Text] [Related]
2. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator.
Matsui D; Hermann C; Klein J; Berkovitch M; Olivieri N; Koren G
J Clin Pharmacol; 1994 Sep; 34(9):944-9. PubMed ID: 7983239
[TBL] [Abstract][Full Text] [Related]
3. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
4. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
[TBL] [Abstract][Full Text] [Related]
5. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia.
Matsui D; Klein J; Hermann C; Grunau V; McClelland R; Chung D; St-Louis P; Olivieri N; Koren G
Clin Pharmacol Ther; 1991 Sep; 50(3):294-8. PubMed ID: 1914364
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
Gomber S; Saxena R; Madan N
Indian Pediatr; 2004 Jan; 41(1):21-7. PubMed ID: 14767084
[TBL] [Abstract][Full Text] [Related]
8. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
Kontoghiorghes GJ; Aldouri MA; Sheppard L; Hoffbrand AV
Lancet; 1987 Jun; 1(8545):1294-5. PubMed ID: 2884415
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
10. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
Olivieri NF; Brittenham GM; Matsui D; Berkovitch M; Blendis LM; Cameron RG; McClelland RA; Liu PP; Templeton DM; Koren G
N Engl J Med; 1995 Apr; 332(14):918-22. PubMed ID: 7877649
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with deferiprone in a L1 veteran.
Meo A; Ruggeri A; La Rosa MA; Zanghì L; Kordes U; Fischer R
Eur J Haematol; 2005 Jun; 74(6):523-5. PubMed ID: 15876257
[TBL] [Abstract][Full Text] [Related]
12. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
Olivieri NF; Koren G; Hermann C; Bentur Y; Chung D; Klein J; St Louis P; Freedman MH; McClelland RA; Templeton DM
Lancet; 1990 Nov; 336(8726):1275-9. PubMed ID: 1978115
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R
Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
15. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
16. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of iron overload states with oral administration of the chelator agent, L1 (Deferiprone)].
Cermák J; Brabec V
Vnitr Lek; 1994 Sep; 40(9):586-90. PubMed ID: 7975362
[TBL] [Abstract][Full Text] [Related]
18. Combined oral and parenteral iron chelation in beta thalassaemia major.
Balveer K; Pyar K; Wonke B
Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
[TBL] [Abstract][Full Text] [Related]
19. How often is medication taken as prescribed? A novel assessment technique.
Cramer JA; Mattson RH; Prevey ML; Scheyer RD; Ouellette VL
JAMA; 1989 Jun; 261(22):3273-7. PubMed ID: 2716163
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
Thuma PE; Olivieri NF; Mabeza GF; Biemba G; Parry D; Zulu S; Fassos FF; McClelland RA; Koren G; Brittenham GM; Gordeuk VR
Am J Trop Med Hyg; 1998 Mar; 58(3):358-64. PubMed ID: 9546419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
